Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report

Takeshi Sato, Koji Muroya, Yumi Asakura, Akihiro Yachie, Gen Nishimura, Noriko Aida, Jiro Machida, Yukichi Tanaka, Tomonobu Hasegawa, Masanori Adachi

Research output: Contribution to journalArticle

Abstract

We report on a boy who presented with hypophosphatemic rickets with elevated serum fibroblast growth factor 23 (FGF23) and polyostotic osteolytic lesions at age 2 years. Tumor-induced hypophosphatemic rickets was suspected; however, bone biopsy for osteolytic changes revealed no tumorous change, except for irregularly dilated vessels associated with osteoclasts and fibrous proliferation. Venous sampling failed to point to FGF23-producing foci. After alfacalcidol and phosphate supplementation, the rachitic skeletal changes improved, but FGF23 increased and new osteolytic lesions developed. Serum levels of neopterin and a few cytokines, including plasma transforming growth factor-β and soluble tumor necrosis factor receptor type II, were elevated. At age 4 years, high doses of phosphate resulted in increased serum phosphate levels, decreased neopterin and cytokines, decreased FGF23, and stabilization of osteolysis. We excluded germline mutations in PHEX, FGF23, DMP1, and ENPP1 (genes for hereditary hypophosphatemic rickets) and somatic mutations in the GNAS and HRAS/KRAS (the disease-causing genes for McCune-Albright syndrome and linear nevus sebaceous syndrome, respectively). We could not perform octreotide scintigraphy or fluorodeoxyglucose-positron emission tomography, and thus could not completely exclude occult FGF23-producing tumors. However, considering the course of the disease, it is intriguing to assume that dysregulation of osteoclast-macrophage lineage may have induced increased neopterin levels, increased cytokine levels, osteolytic process, and possibly FGF23 overproduction.

Original languageEnglish
Pages (from-to)2430-2434
Number of pages5
JournalAmerican Journal of Medical Genetics, Part A
Volume167
Issue number10
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Hypophosphatemic Rickets
Osteolysis
Neopterin
Serum
Phosphates
Osteoclasts
Cytokines
Sebaceous of Jadassohn Nevus
Familial Hypophosphatemic Rickets
Polyostotic Fibrous Dysplasia
Receptors, Tumor Necrosis Factor, Type II
Rickets
Octreotide
Germ-Line Mutation
Transforming Growth Factors
fibroblast growth factor 23
Radionuclide Imaging
Positron-Emission Tomography
Genes
Neoplasms

Keywords

  • Fibroblast growth factor 23
  • Hypophosphatemic rickets
  • Polyostotic osteolysis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23 : A case report. / Sato, Takeshi; Muroya, Koji; Asakura, Yumi; Yachie, Akihiro; Nishimura, Gen; Aida, Noriko; Machida, Jiro; Tanaka, Yukichi; Hasegawa, Tomonobu; Adachi, Masanori.

In: American Journal of Medical Genetics, Part A, Vol. 167, No. 10, 01.10.2015, p. 2430-2434.

Research output: Contribution to journalArticle

Sato, Takeshi ; Muroya, Koji ; Asakura, Yumi ; Yachie, Akihiro ; Nishimura, Gen ; Aida, Noriko ; Machida, Jiro ; Tanaka, Yukichi ; Hasegawa, Tomonobu ; Adachi, Masanori. / Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23 : A case report. In: American Journal of Medical Genetics, Part A. 2015 ; Vol. 167, No. 10. pp. 2430-2434.
@article{50577ece4db04466b530ef00c24a4b5f,
title = "Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report",
abstract = "We report on a boy who presented with hypophosphatemic rickets with elevated serum fibroblast growth factor 23 (FGF23) and polyostotic osteolytic lesions at age 2 years. Tumor-induced hypophosphatemic rickets was suspected; however, bone biopsy for osteolytic changes revealed no tumorous change, except for irregularly dilated vessels associated with osteoclasts and fibrous proliferation. Venous sampling failed to point to FGF23-producing foci. After alfacalcidol and phosphate supplementation, the rachitic skeletal changes improved, but FGF23 increased and new osteolytic lesions developed. Serum levels of neopterin and a few cytokines, including plasma transforming growth factor-β and soluble tumor necrosis factor receptor type II, were elevated. At age 4 years, high doses of phosphate resulted in increased serum phosphate levels, decreased neopterin and cytokines, decreased FGF23, and stabilization of osteolysis. We excluded germline mutations in PHEX, FGF23, DMP1, and ENPP1 (genes for hereditary hypophosphatemic rickets) and somatic mutations in the GNAS and HRAS/KRAS (the disease-causing genes for McCune-Albright syndrome and linear nevus sebaceous syndrome, respectively). We could not perform octreotide scintigraphy or fluorodeoxyglucose-positron emission tomography, and thus could not completely exclude occult FGF23-producing tumors. However, considering the course of the disease, it is intriguing to assume that dysregulation of osteoclast-macrophage lineage may have induced increased neopterin levels, increased cytokine levels, osteolytic process, and possibly FGF23 overproduction.",
keywords = "Fibroblast growth factor 23, Hypophosphatemic rickets, Polyostotic osteolysis",
author = "Takeshi Sato and Koji Muroya and Yumi Asakura and Akihiro Yachie and Gen Nishimura and Noriko Aida and Jiro Machida and Yukichi Tanaka and Tomonobu Hasegawa and Masanori Adachi",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/ajmg.a.37193",
language = "English",
volume = "167",
pages = "2430--2434",
journal = "American Journal of Medical Genetics",
issn = "1552-4868",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23

T2 - A case report

AU - Sato, Takeshi

AU - Muroya, Koji

AU - Asakura, Yumi

AU - Yachie, Akihiro

AU - Nishimura, Gen

AU - Aida, Noriko

AU - Machida, Jiro

AU - Tanaka, Yukichi

AU - Hasegawa, Tomonobu

AU - Adachi, Masanori

PY - 2015/10/1

Y1 - 2015/10/1

N2 - We report on a boy who presented with hypophosphatemic rickets with elevated serum fibroblast growth factor 23 (FGF23) and polyostotic osteolytic lesions at age 2 years. Tumor-induced hypophosphatemic rickets was suspected; however, bone biopsy for osteolytic changes revealed no tumorous change, except for irregularly dilated vessels associated with osteoclasts and fibrous proliferation. Venous sampling failed to point to FGF23-producing foci. After alfacalcidol and phosphate supplementation, the rachitic skeletal changes improved, but FGF23 increased and new osteolytic lesions developed. Serum levels of neopterin and a few cytokines, including plasma transforming growth factor-β and soluble tumor necrosis factor receptor type II, were elevated. At age 4 years, high doses of phosphate resulted in increased serum phosphate levels, decreased neopterin and cytokines, decreased FGF23, and stabilization of osteolysis. We excluded germline mutations in PHEX, FGF23, DMP1, and ENPP1 (genes for hereditary hypophosphatemic rickets) and somatic mutations in the GNAS and HRAS/KRAS (the disease-causing genes for McCune-Albright syndrome and linear nevus sebaceous syndrome, respectively). We could not perform octreotide scintigraphy or fluorodeoxyglucose-positron emission tomography, and thus could not completely exclude occult FGF23-producing tumors. However, considering the course of the disease, it is intriguing to assume that dysregulation of osteoclast-macrophage lineage may have induced increased neopterin levels, increased cytokine levels, osteolytic process, and possibly FGF23 overproduction.

AB - We report on a boy who presented with hypophosphatemic rickets with elevated serum fibroblast growth factor 23 (FGF23) and polyostotic osteolytic lesions at age 2 years. Tumor-induced hypophosphatemic rickets was suspected; however, bone biopsy for osteolytic changes revealed no tumorous change, except for irregularly dilated vessels associated with osteoclasts and fibrous proliferation. Venous sampling failed to point to FGF23-producing foci. After alfacalcidol and phosphate supplementation, the rachitic skeletal changes improved, but FGF23 increased and new osteolytic lesions developed. Serum levels of neopterin and a few cytokines, including plasma transforming growth factor-β and soluble tumor necrosis factor receptor type II, were elevated. At age 4 years, high doses of phosphate resulted in increased serum phosphate levels, decreased neopterin and cytokines, decreased FGF23, and stabilization of osteolysis. We excluded germline mutations in PHEX, FGF23, DMP1, and ENPP1 (genes for hereditary hypophosphatemic rickets) and somatic mutations in the GNAS and HRAS/KRAS (the disease-causing genes for McCune-Albright syndrome and linear nevus sebaceous syndrome, respectively). We could not perform octreotide scintigraphy or fluorodeoxyglucose-positron emission tomography, and thus could not completely exclude occult FGF23-producing tumors. However, considering the course of the disease, it is intriguing to assume that dysregulation of osteoclast-macrophage lineage may have induced increased neopterin levels, increased cytokine levels, osteolytic process, and possibly FGF23 overproduction.

KW - Fibroblast growth factor 23

KW - Hypophosphatemic rickets

KW - Polyostotic osteolysis

UR - http://www.scopus.com/inward/record.url?scp=84941260950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941260950&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.37193

DO - 10.1002/ajmg.a.37193

M3 - Article

C2 - 26059403

AN - SCOPUS:84941260950

VL - 167

SP - 2430

EP - 2434

JO - American Journal of Medical Genetics

JF - American Journal of Medical Genetics

SN - 1552-4868

IS - 10

ER -